UMAIR MALIK: Open Payments
NPI 1770679938 · THORNDALE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,751 in 49 payments from 20 companies in 2025. Trend: 2023 $1,760 · 2024 $1,918 · 2025 $1,751
Food & beverage: $1,751
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $416 |
| AstraZeneca Pharmaceuticals LP | 3 | $284 |
| ABBVIE INC. | 6 | $234 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $116 |
| Calliditas Therapeutics US Inc. | 2 | $112 |
| Braeburn Inc. | 4 | $102 |
| Lilly USA, LLC | 3 | $68 |
| Novo Nordisk Inc | 3 | $65 |
| Aurinia Pharma U.S., Inc. | 2 | $47 |
| Indivior Inc. | 2 | $45 |
Products named: CAPLYTA, BREZTRI, VRAYLAR, TARPEYO, BRIXADI, XIFAXAN, LUPKYNIS, Rybelsus.
Industry payments across PA — which companies pay providers there.
